Opaleye Management Inc. 13F holdings, Q4 2024
Holdings as of December 31, 2024 · filings on SEC EDGAR · latest filing →
Opaleye Management Inc. disclosed 39 US equity positions worth $571.4m in its Q4 2024 13F filing. The largest position was HROW at 23.4% of the reported book, followed by TGTX and CDXS. Against the Q3 2024 filing, it opened 6 new positions, added to 13 and reduced 11 among the top 39 holdings.
What did Opaleye Management Inc. own in Q4 2024? Top 39 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2024 |
|---|---|---|---|---|---|---|---|
| 1 | HROW HARROW HEALTH INC | 23.4% | $133.9m | 3,990,000 | 0% | held | |
| 2 | TGTX TG THERAPEUTICS INC | Healthcare | 11.9% | $68.0m | 2,260,000 | -1% | reduced |
| 3 | CDXS CODEXIS INC | Healthcare | 7.4% | $42.2m | 8,840,000 | 1% | added |
| 4 | ETON ETON PHARMACEUTICALS INC | 6.6% | $38.0m | 2,852,070 | 3% | added | |
| 5 | OCUL OCULAR THERAPEUTIX INC | Healthcare | 6.5% | $37.1m | 4,342,500 | -14% | reduced |
| 6 | ARVN ARVINAS INC | Healthcare | 5.9% | $33.6m | 1,625,000 | 29% | added |
| 7 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 4.9% | $28.0m | 500,000 | 0% | held |
| 8 | IMNM IMMUNOME INC | Healthcare | 3.8% | $21.7m | 2,040,000 | 65% | added |
| 9 | LQDA LIQUIDIA CORPORATION | Healthcare | 3.5% | $20.0m | 1,698,142 | 0% | held |
| 10 | EWTX EDGEWISE THERAPEUTICS INC | 2.2% | $12.8m | 480,000 | -8% | reduced | |
| 11 | DNA GINKGO BIOWORKS HOLDINGS | 2.1% | $11.8m | 1,200,000 | 46% | added | |
| 12 | CRGX CARGO THERAPEUTICS INC | 1.9% | $10.8m | 750,000 | 39% | added | |
| 13 | TARA PROTARA THERAPEUTICS INC | 1.7% | $9.6m | 1,825,000 | 9% | added | |
| 14 | TRVI TREVI THERAPEUTICS INC | Healthcare | 1.7% | $9.5m | 2,317,500 | -10% | reduced |
| 15 | JSPR JASPER THERAPEUTICS INC | 1.5% | $8.6m | 400,000 | 13% | added | |
| 16 | NEWAMSTERDAM PHARMA COMPANY | 1.5% | $8.4m | 325,000 | -3% | reduced | |
| 17 | ACELYRIN INC | 1.3% | $7.2m | 2,235,000 | 18% | added | |
| 18 | NRIX NURIX THERAPEUTICS INC | Healthcare | 1.2% | $7.1m | 378,500 | -10% | reduced |
| 19 | XOMA CORP DEL | 1.1% | $6.6m | 250,000 | 0% | held | |
| 20 | PCVX VAXCYTE INC | Healthcare | 1.1% | $6.1m | 75,000 | -12% | reduced |
| 21 | GOSSAMER BIO INC | 1.1% | $6.1m | 11,500,000 | 44% | added | |
| 22 | ZNTL ZENTALIS PHARMACEUTICALS INC | Healthcare | 0.9% | $5.4m | 1,767,500 | 83% | added |
| 23 | BDSX BIODESIX INC | 0.9% | $5.3m | 3,465,000 | -9% | reduced | |
| 24 | KARYOPHARM THERAPEUTICS INC | 0.8% | $4.7m | 6,000,000 | 0% | held | |
| 25 | NUVALENT INC | 0.8% | $4.6m | 58,500 | -9% | reduced | |
| 26 | GOSS GOSSAMER BIO INC | Healthcare | 0.7% | $4.1m | 4,490,000 | 23% | added |
| 27 | PTGX PROTAGONIST THERAPEUTICS INC | Healthcare | 0.7% | $4.1m | 105,000 | 0% | held |
| 28 | EPIEUR ESSA PHARMA INC | 0.7% | $4.0m | 2,209,998 | – | new | |
| 29 | ABCL ABCELLERA BIOLOGICS INC | Healthcare | 0.5% | $2.8m | 965,000 | 21% | added |
| 30 | URGN UROGEN PHARMA LTD | Healthcare | 0.4% | $2.3m | 220,000 | -46% | reduced |
| 31 | RZLT REZOLUTE INC | 0.4% | $2.3m | 465,000 | -0% | held | |
| 32 | IMTX IMMATICS NV | Healthcare | 0.2% | $1.2m | 165,000 | – | new |
| 33 | IBIO IBIO INC | 0.2% | $918.8k | 375,000 | 0% | held | |
| 34 | LXEO LEXEO THERAPEUTICS INC | Healthcare | 0.1% | $855.4k | 130,000 | – | new |
| 35 | RGNX REGENXBIO Inc | Healthcare | 0.1% | $618.4k | 80,000 | – | new |
| 36 | VTYXUSD VENTYX BIOSCIENCES | 0.1% | $613.2k | 280,000 | – | new | |
| 37 | PEPG PEPGEN INC | Healthcare | 0.1% | $416.9k | 110,000 | -39% | reduced |
| 38 | STOK STOKE THERAPEUTICS INC | Healthcare | 0.0% | $275.8k | 25,000 | – | new |
| 39 | ADGM ADAGIO MED HLDGS INC | 0.0% | $116.1k | 110,571 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.